Last reviewed · How we verify

OnabotulinumtoxinA 100 UNT

University of South Florida · FDA-approved active Small molecule

OnabotulinumtoxinA 100 UNT is a Botulinum toxin Small molecule drug developed by University of South Florida. It is currently FDA-approved for Cervical dystonia, Blepharospasm, Strabismus. Also known as: BOTOX.

OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Strabismus.

At a glance

Generic nameOnabotulinumtoxinA 100 UNT
Also known asBOTOX
SponsorUniversity of South Florida
Drug classBotulinum toxin
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology; Dermatology; Aesthetics
PhaseFDA-approved

Mechanism of action

OnabotulinumtoxinA is a botulinum toxin serotype A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release. This prevents neuromuscular transmission, resulting in temporary paralysis of injected muscles. The effect is localized to the injection site and gradually reverses over 3-4 months as new neuromuscular junctions form.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about OnabotulinumtoxinA 100 UNT

What is OnabotulinumtoxinA 100 UNT?

OnabotulinumtoxinA 100 UNT is a Botulinum toxin drug developed by University of South Florida, indicated for Cervical dystonia, Blepharospasm, Strabismus.

How does OnabotulinumtoxinA 100 UNT work?

OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is OnabotulinumtoxinA 100 UNT used for?

OnabotulinumtoxinA 100 UNT is indicated for Cervical dystonia, Blepharospasm, Strabismus, Chronic migraine, Overactive bladder.

Who makes OnabotulinumtoxinA 100 UNT?

OnabotulinumtoxinA 100 UNT is developed and marketed by University of South Florida (see full University of South Florida pipeline at /company/university-of-south-florida).

Is OnabotulinumtoxinA 100 UNT also known as anything else?

OnabotulinumtoxinA 100 UNT is also known as BOTOX.

What drug class is OnabotulinumtoxinA 100 UNT in?

OnabotulinumtoxinA 100 UNT belongs to the Botulinum toxin class. See all Botulinum toxin drugs at /class/botulinum-toxin.

What development phase is OnabotulinumtoxinA 100 UNT in?

OnabotulinumtoxinA 100 UNT is FDA-approved (marketed).

What are the side effects of OnabotulinumtoxinA 100 UNT?

Common side effects of OnabotulinumtoxinA 100 UNT include Headache, Neck pain, Injection site pain, Muscle weakness, Dysphagia, Ptosis.

What does OnabotulinumtoxinA 100 UNT target?

OnabotulinumtoxinA 100 UNT targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Botulinum toxin.

Related